Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ABBV-547 · 1 trial · 1 indication
An AE is defined as any untoward medical occurrence in a patient or clinical investigation in which a participant is administered a pharmaceutical product which does not necessarily have a causal relationship with this treatment.
| Arm | Type | Description |
|---|---|---|
| Group 1: ABBV-547 & Placebo | EXPERIMENTAL | Participants will receive either ABBV-547 or placebo. |
| Group 2: ABBV-547 & Placebo | EXPERIMENTAL | Participants will receive either ABBV-547 or placebo. |
| Group 3: ABBV-547 & Placebo | EXPERIMENTAL | Participants will receive either ABBV-547 or placebo. |
| Group 4: ABBV-547 & Placebo | EXPERIMENTAL | Participants will receive either ABBV-547 or placebo. |
| Group 5: ABBV-547 & Placebo | EXPERIMENTAL | Participants will receive either ABBV-547 or placebo. |
| Group 6: ABBV-547 & Placebo | EXPERIMENTAL | Participants will receive either ABBV-547 or placebo. |
| Group 7: ABBV-547 & Placebo | EXPERIMENTAL | Participants will receive either ABBV-547 or placebo. |
| Group 8: ABBV-547 & Placebo | EXPERIMENTAL | Japanese participants will receive either ABBV-547 or placebo. |
| Group 9: ABBV-547 & Placebo | EXPERIMENTAL | Han Chinese participants will receive either ABBV-547 or placebo. |
| Group 10: ABBV-547 & Placebo | EXPERIMENTAL | Participants will receive either ABBV-547 or placebo. |
| Name | Type | Description |
|---|---|---|
| ABBV-547 | DRUG | Parental Administration |
| ABBV-547 Placebo | DRUG | Parental Administration |
Inclusion Criteria: * A condition of general good health, based upon the results of a medical history, physical examination, vital signs, laboratory profile and a 12-lead electrocardiogram (ECG). * Part 1: BMI is \>= 18.0 to \<= 29.9 kg/m\^2 after rounding to the tenths decimal at Screening. BMI is...
ABBV-547 is an investigational small molecule being studied in healthy volunteers. It is currently in Phase 1 clinical development to evaluate how the drug moves through the body, its adverse events, and how the body tolerates ABBV-547 injections. It is not yet approved for any medical condition.
ABBV-547 is being developed by AbbVie Inc., a biopharmaceutical company traded on the New York Stock Exchange under the ticker ABBV. The company is conducting a Phase 1 clinical trial to evaluate the drug's pharmacokinetics, safety, and tolerability in healthy volunteers.
ABBV-547 is in Phase 1 clinical development. It is an investigational drug being studied in a Phase 1 trial that is active but not recruiting participants. The drug has not been approved by regulatory authorities and remains in early-stage clinical testing.
ABBV-547 is being evaluated in one Phase 1 clinical trial, identified as NCT07232004. This study is assessing how the drug moves through the body, adverse events, and tolerability of ABBV-547 injections in healthy volunteers. The trial is active but not recruiting and has an enrollment of 121 participants.
Yes, ABBV-547 is a small molecule drug. It is being developed as an injectable formulation and is currently in Phase 1 clinical testing in healthy volunteers. The ongoing trial is designed to evaluate the drug's pharmacokinetics, safety, and tolerability.